Cita APA

Teramachi, J., Tenshin, H., Hiasa, M., Oda, A., Bat-Erdene, A., Harada, T., . . . Abe, M. (2020). TAK1 is a pivotal therapeutic target for tumor progression and bone destruction in myeloma. Haematologica.

Chicago Style Citation

Teramachi, Jumpei, et al. "TAK1 Is a Pivotal Therapeutic Target for Tumor Progression and Bone Destruction in Myeloma." Haematologica 2020.

Cita MLA

Teramachi, Jumpei, et al. "TAK1 Is a Pivotal Therapeutic Target for Tumor Progression and Bone Destruction in Myeloma." Haematologica 2020.